MX2022013065A - Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente. - Google Patents
Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente.Info
- Publication number
- MX2022013065A MX2022013065A MX2022013065A MX2022013065A MX2022013065A MX 2022013065 A MX2022013065 A MX 2022013065A MX 2022013065 A MX2022013065 A MX 2022013065A MX 2022013065 A MX2022013065 A MX 2022013065A MX 2022013065 A MX2022013065 A MX 2022013065A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- cell
- therapy product
- expansion
- cell therapy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000002659 cell therapy Methods 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/08—Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
- G06Q10/083—Shipping
- G06Q10/0832—Special goods or special handling procedures, e.g. handling of hazardous or fragile goods
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Business, Economics & Management (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Business, Economics & Management (AREA)
- Economics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Human Resources & Organizations (AREA)
- Operations Research (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- Tourism & Hospitality (AREA)
- Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Development Economics (AREA)
- Entrepreneurship & Innovation (AREA)
Abstract
Un método para coordinar la manufactura de un producto de terapia celular expandido para un paciente puede incluir recibir una solicitud de pedido de células para expandir el producto de terapia celular para el paciente; generar un identificador específico del paciente o un identificador de orden de célula asociado con la solicitud de orden de célula; e iniciar un proceso para expandir el producto de terapia celular de al menos parte de un tumor sólido obtenido del paciente. Si los parámetros de aceptación para el producto de terapia celular de expansión no cumplen con ciertos criterios de aceptación en un segundo momento posterior al primer momento en el proceso de expansión, se determina si se vuelve a realizar la expansión del producto de terapia celular usando la técnica de expansión celular es posible desde el primer punto de tiempo basado en los parámetros de aceptación en el segundo punto de tiempo. Si es posible repetir la expansión, los eventos de tratamiento del paciente que usan el producto de terapia celular expandida se reprograman.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063013942P | 2020-04-22 | 2020-04-22 | |
US202163155711P | 2021-03-02 | 2021-03-02 | |
US202163159806P | 2021-03-11 | 2021-03-11 | |
PCT/US2021/028709 WO2021216920A1 (en) | 2020-04-22 | 2021-04-22 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013065A true MX2022013065A (es) | 2022-12-08 |
Family
ID=76138096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013065A MX2022013065A (es) | 2020-04-22 | 2021-04-22 | Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente. |
Country Status (12)
Country | Link |
---|---|
US (5) | US20210335467A1 (es) |
EP (1) | EP4139440A1 (es) |
JP (1) | JP2023524639A (es) |
KR (1) | KR20230037069A (es) |
CN (1) | CN115997008A (es) |
AU (1) | AU2021258257A1 (es) |
BR (1) | BR112022021020A2 (es) |
CA (1) | CA3176356A1 (es) |
IL (1) | IL297442A (es) |
MX (1) | MX2022013065A (es) |
TW (1) | TW202206592A (es) |
WO (1) | WO2021216920A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3041678A1 (en) * | 2016-10-26 | 2018-05-03 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
US11024160B2 (en) * | 2016-11-07 | 2021-06-01 | Nio Usa, Inc. | Feedback performance control and tracking |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
IL294098A (en) | 2019-12-20 | 2022-08-01 | Instil Bio Uk Ltd | Devices and methods for isolating lymphocytes infiltrating tumors and their use |
WO2023225048A1 (en) * | 2022-05-17 | 2023-11-23 | Synthego Corporation | Systems and methods for engageable platforms and modules for cell processing |
US20240086416A1 (en) * | 2022-09-09 | 2024-03-14 | Honeywell International Inc. | Methods and systems for integrating external systems of records with final report |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US6352694B1 (en) * | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US7922073B2 (en) * | 1997-10-21 | 2011-04-12 | Carlos De La Huerga | Vial printing method and apparatus |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
MXPA01006422A (es) | 1998-12-23 | 2002-06-04 | Pfizer Inc Abgenix Inc | Anticuerpos monoclonales humanos de ctla-4. |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
US20030235908A1 (en) * | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
NZ553687A (en) | 2000-03-30 | 2010-03-26 | Whitehead Biomedical Inst | RNA sequence-specific mediators of RNA interference |
WO2002037938A2 (en) * | 2000-10-24 | 2002-05-16 | Oncosis Llc | Method and device for selectively targeting cells within a three -dimensional specimen |
EP1353701B1 (en) | 2000-10-31 | 2011-12-21 | PR Pharmaceuticals, Inc. | Methods for producing compositions for enhanced delivery of bioactive molecules |
SI1407044T2 (en) | 2000-12-01 | 2018-03-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Small RNA molecules that mediate RNA interference |
US6615092B2 (en) * | 2001-03-05 | 2003-09-02 | Dell Products L.P. | Method, system and facility for controlling resource allocation within a manufacturing environment |
US20030175242A1 (en) * | 2001-09-17 | 2003-09-18 | Micheal Gruenberg | Cell therapy system |
DE10161064A1 (de) | 2001-12-12 | 2003-07-03 | Siemens Ag | System und Verfahren zur Kommunikation zwischen Softwareapplikationen, insbesondere MES-Applikationen |
US20030149608A1 (en) | 2002-02-06 | 2003-08-07 | Kall Jonathan J. | Suite of configurable supply chain infrastructure modules for deploying collaborative e-manufacturing solutions |
DK2330181T3 (en) * | 2002-04-08 | 2019-03-25 | Octane Biotech Inc | AUTOMATED Tissue Manipulation System |
JP2005529873A (ja) | 2002-04-12 | 2005-10-06 | メダレックス インコーポレイテッド | Ctla−4抗体を使用した治療の方法 |
US9565275B2 (en) | 2012-02-09 | 2017-02-07 | Rockwell Automation Technologies, Inc. | Transformation of industrial data into useful cloud information |
US7076312B2 (en) | 2002-08-02 | 2006-07-11 | Fisher-Rosemount Systems, Inc. | Integrated electronic signatures for approval of process control and safety system software objects |
WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
PT3284753T (pt) | 2002-10-17 | 2020-05-04 | Genmab As | Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla |
US7962361B2 (en) | 2002-11-07 | 2011-06-14 | Novitaz | Customer relationship management system for physical locations |
US20060246123A1 (en) | 2003-03-12 | 2006-11-02 | Eli Gilboa | Oligonucleotide mimetics |
EP3450538B1 (en) | 2003-10-08 | 2021-08-25 | Wilson Wolf Manufacturing Corporation | Cell culture methods and devices utilizing gas permeable materials |
KR100845354B1 (ko) | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항-ctla-4 항체의 용도 |
US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
US7444197B2 (en) * | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
EP1781083A4 (en) | 2004-06-18 | 2009-09-09 | Univ California | SEQUENCES OF BRASSICA INDEHISCENT1 |
US8239749B2 (en) | 2004-06-25 | 2012-08-07 | Apple Inc. | Procedurally expressing graphic objects for web pages |
EP1793858A4 (en) | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
CN101238218A (zh) * | 2005-05-20 | 2008-08-06 | 维克西斯公司 | 初级细胞的转导 |
CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
US20070143165A1 (en) | 2005-08-12 | 2007-06-21 | John Roberts | Customer relationship management system and method |
EP1954311A4 (en) | 2005-12-07 | 2009-12-23 | Medarex Inc | CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY |
US20100143918A1 (en) | 2007-01-19 | 2010-06-10 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
AU2007241023B2 (en) | 2006-03-30 | 2013-11-28 | University Of California | Methods and compositions for localized secretion of anti-CTLA-4 antibodies |
JP2008066402A (ja) | 2006-09-05 | 2008-03-21 | Fujifilm Corp | 撮像素子および撮像装置 |
CA2666509C (en) | 2006-10-16 | 2017-05-09 | Hospira, Inc. | System and method for comparing and utilizing activity information and configuration information from multiple medical device management systems |
US8041444B2 (en) | 2006-12-22 | 2011-10-18 | Harris Stratex Networks Operating Corporation | Intelligent production station and production method |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
EP3741851A1 (en) | 2007-10-18 | 2020-11-25 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
JP2012500013A (ja) | 2008-08-18 | 2012-01-05 | マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー.ファウ. | Hsp90阻害剤に対する感受性 |
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
CA2744236C (en) | 2009-02-12 | 2021-03-16 | Cell Signaling Technology, Inc. | Mutant ros expression in human cancer |
KR101312053B1 (ko) | 2009-02-25 | 2013-09-25 | (주)리치스톤 | 스크롤 유체기계 |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
WO2012033537A1 (en) * | 2010-09-08 | 2012-03-15 | Nodality, Inc. | Benchmarks for normal cell identification |
PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
JP2013512694A (ja) | 2009-12-08 | 2013-04-18 | ウィルソン ウォルフ マニュファクチャリング コーポレイション | 養子細胞療法のための細胞を培養する方法 |
TWI518325B (zh) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US9783578B2 (en) | 2010-06-25 | 2017-10-10 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
AU2012288413B2 (en) | 2011-07-24 | 2016-10-13 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
TW201312117A (zh) | 2011-07-28 | 2013-03-16 | Univ Pennsylvania | 用以診斷與漿液相關之腫瘤細胞的症狀及特性的方法及試劑 |
AU2012324644B2 (en) | 2011-10-21 | 2014-08-28 | Cell Medica Limited | Device for the aseptic expansion of cells |
CA2854832C (en) | 2011-11-07 | 2023-05-23 | Ingenuity Systems, Inc. | Methods and systems for identification of causal genomic variants |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
US20140088985A1 (en) | 2012-03-30 | 2014-03-27 | Elizur Corporation | Providing healthcare solutions and workflow management |
US20150056193A1 (en) | 2012-04-18 | 2015-02-26 | Cell Signaling Technology, Inc. | Egfr and ros1 kinase in cancer |
CA2872504A1 (en) | 2012-05-18 | 2013-11-21 | Wilson Wolf Manufacturing Corporation | A static animal cell culture and cell recovery |
EP3401402B1 (en) | 2012-06-08 | 2020-10-14 | Alkermes Pharma Ireland Limited | Ligands modified by circular permutation as agonists and antagonists |
IL302514A (en) | 2012-06-11 | 2023-07-01 | Wilson Wolf Mfg Corporation | Improved cell culture methods for stress cell therapy |
US20140244351A1 (en) | 2013-02-28 | 2014-08-28 | Single Funnel Pty Ltd | Customer relationship management (crm) systems |
AU2013379772B2 (en) | 2013-03-01 | 2018-09-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing enriched populations of tumor-reactive T cells from tumor |
EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
AU2014262481A1 (en) | 2013-05-10 | 2015-11-26 | Foundation Medicine, Inc. | Analysis of genetic variants |
US20140372147A1 (en) | 2013-06-13 | 2014-12-18 | NaviNet, Inc. | Systems, methods, and environment for identification and processing of medical events |
WO2014210036A1 (en) | 2013-06-24 | 2014-12-31 | Wilson Wolf Manufacturing Corporation | Closed system device and methods for gas permeable cell culture process |
HUP1300432A2 (hu) | 2013-07-10 | 2015-01-28 | Tamas Kardos | Downhill kerékpár szerkezet javított felfüggesztéssel |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
EP3041828B1 (en) | 2013-09-06 | 2018-05-23 | Aurigene Discovery Technologies Limited | 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
HRP20221262T1 (hr) | 2013-09-13 | 2022-12-09 | Beigene Switzerland Gmbh | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava |
US10233425B2 (en) | 2013-09-16 | 2019-03-19 | The Trustees Of The University Of Pennsylvania | CD137 enrichment for efficient tumor infiltrating lymphocyte selection |
US9678505B2 (en) | 2013-10-14 | 2017-06-13 | Invensys Systems, Inc. | Line management in manufacturing execution system |
CN112080467A (zh) | 2014-03-20 | 2020-12-15 | H.李莫菲特癌症中心研究院 | 用于过继细胞疗法的肿瘤浸润淋巴细胞 |
WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
MX370018B (es) * | 2014-04-25 | 2019-11-28 | Bluebird Bio Inc | Metodos mejorados para la elaboracion de terapias celulares adoptivas. |
US20170107490A1 (en) | 2014-06-11 | 2017-04-20 | Polybiocept Ab | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
CA2963362A1 (en) | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation |
EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
US10108965B2 (en) | 2015-07-14 | 2018-10-23 | Ujet, Inc. | Customer communication system including service pipeline |
MX2018010362A (es) | 2016-02-29 | 2019-03-28 | Found Medicine Inc | Metodos y sistemas para evaluar carga mutacional de tumores. |
WO2017210677A1 (en) | 2016-06-03 | 2017-12-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1α) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) |
WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
JP7265989B2 (ja) | 2016-10-25 | 2023-04-27 | ウロゲン ファーマ リミテッド | 体腔の免疫調節治療 |
CA3041678A1 (en) | 2016-10-26 | 2018-05-03 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
JP2019534308A (ja) | 2016-11-10 | 2019-11-28 | ネクター セラピューティクス | 免疫療法的腫瘍治療方法 |
BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
CN110383385B (zh) | 2016-12-08 | 2023-07-25 | 生命科技股份有限公司 | 从肿瘤样品中检测突变负荷的方法 |
CN110167598A (zh) | 2017-01-10 | 2019-08-23 | 尼克塔治疗公司 | Tlr激动剂化合物的多臂聚合物缀合物以及相关的免疫治疗方法 |
JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
WO2018204760A1 (en) | 2017-05-05 | 2018-11-08 | David Weiner | Ctla4 antibodies and vaccine combinations and use of same for immunotherapy |
CN110662762A (zh) | 2017-05-24 | 2020-01-07 | 诺华股份有限公司 | 抗体细胞因子移植蛋白和用于治疗癌症的方法 |
TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
EP3661955A4 (en) | 2017-08-03 | 2021-05-26 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
CN111315403A (zh) * | 2017-09-15 | 2020-06-19 | 凯德药业股份有限公司 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
CA3102859A1 (en) | 2018-07-03 | 2020-01-09 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
US20210038684A1 (en) | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
-
2021
- 2021-04-22 TW TW110114589A patent/TW202206592A/zh unknown
- 2021-04-22 JP JP2022562933A patent/JP2023524639A/ja active Pending
- 2021-04-22 CN CN202180044820.9A patent/CN115997008A/zh active Pending
- 2021-04-22 CA CA3176356A patent/CA3176356A1/en active Pending
- 2021-04-22 US US17/238,092 patent/US20210335467A1/en active Pending
- 2021-04-22 IL IL297442A patent/IL297442A/en unknown
- 2021-04-22 EP EP21728131.0A patent/EP4139440A1/en active Pending
- 2021-04-22 BR BR112022021020A patent/BR112022021020A2/pt unknown
- 2021-04-22 MX MX2022013065A patent/MX2022013065A/es unknown
- 2021-04-22 AU AU2021258257A patent/AU2021258257A1/en active Pending
- 2021-04-22 KR KR1020227040425A patent/KR20230037069A/ko active Search and Examination
- 2021-04-22 WO PCT/US2021/028709 patent/WO2021216920A1/en unknown
- 2021-06-24 US US17/357,393 patent/US20210407640A1/en active Pending
- 2021-06-24 US US17/357,360 patent/US20210407639A1/en active Pending
- 2021-11-04 US US17/519,065 patent/US20220059202A1/en active Pending
-
2022
- 2022-01-06 US US17/570,195 patent/US11631483B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20220059202A1 (en) | 2022-02-24 |
TW202206592A (zh) | 2022-02-16 |
US20220122707A1 (en) | 2022-04-21 |
IL297442A (en) | 2022-12-01 |
WO2021216920A1 (en) | 2021-10-28 |
CA3176356A1 (en) | 2021-10-28 |
AU2021258257A1 (en) | 2022-11-10 |
CN115997008A (zh) | 2023-04-21 |
US20210407639A1 (en) | 2021-12-30 |
JP2023524639A (ja) | 2023-06-13 |
US11631483B2 (en) | 2023-04-18 |
EP4139440A1 (en) | 2023-03-01 |
US20210335467A1 (en) | 2021-10-28 |
US20210407640A1 (en) | 2021-12-30 |
KR20230037069A (ko) | 2023-03-15 |
BR112022021020A2 (pt) | 2023-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013065A (es) | Sistemas y metodos para coordinar la manufactura de celulas para inmunoterapia especifica de acuerdo al paciente. | |
Palladini et al. | In silico modeling and in vivo efficacy of cancer-preventive vaccinations | |
EP1504403A4 (en) | TOMOGRAPHIC RECONSTRUCTION OF SMALL OBJECTS USING A "PRIORI" KNOWLEDGE | |
EP4325984A3 (en) | System and method for beam adjustment request | |
WO2008058248A3 (en) | Apparatus and method for introducing particles using a radio frequency quadrupole linear accelerator for semiconductor materials | |
SG11201906166YA (en) | Blockchain service acceptance and consensus method and devices | |
MX2021005021A (es) | Proceso para producir celulas t geneticamente modificadas. | |
EP1315055A3 (en) | System and method for function block execution order generation | |
RU2007105501A (ru) | Преобразование аудиканалов | |
WO2020035089A3 (en) | System and method for blockchain-based decentralized application development | |
CN107679863A (zh) | 一种区块链系统及快速验证区块的方法 | |
WO2019228551A3 (en) | System and method for registering subscribable states in blockchain | |
MX2021008140A (es) | Protocolo basado en ultrasonido para operar un dispositivo implantable. | |
MX2023004330A (es) | Generador de audio y métodos para generar una señal de audio y entrenamiento de un generador de audio. | |
WO2019228553A3 (en) | System and method for registering subscribable sub-states in blockchain | |
WO2023077015A3 (en) | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | |
WO2021077086A8 (en) | Synthesizing audio of a venue | |
EP3832465A3 (en) | Methods, systems, articles of manufacture, and apparatus to optimize thread scheduling | |
MX2022006638A (es) | Producción de 212pb altamente purificados. | |
CN110176988A (zh) | 保证冗余执行体加密行为一致的装置及方法 | |
AR121916A1 (es) | Sistemas y métodos para coordinar la manufactura de células para inmunoterapia paciente específica | |
EP4236189A3 (en) | Distributed biometric comparison framework | |
CN106559212A (zh) | 数据处理方法和装置 | |
US6293291B1 (en) | Method and apparatus for the treatment of objects, preferably wafers | |
AU2003230803A1 (en) | Systems and method for generating an image |